Research programme: CD26 antigen antagonists - Phenomix

Drug Profile

Research programme: CD26 antigen antagonists - Phenomix

Alternative Names: PHX 1004

Latest Information Update: 04 Feb 2011

Price : $50

At a glance

  • Originator Phenomix Corporation
  • Class
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetes mellitus

Most Recent Events

  • 13 Sep 2007 Preclinical development is ongoing
  • 27 Mar 2006 This programme is still in active development
  • 17 Jun 2004 Data presented at the 64th Scientific Sessions of the American Diabetes Association (ADA-2004) have been added to the Diabetes pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top